Amgen, Inc. (AMGN) Receives $194.92 Average Price Target from Analysts

Shares of Amgen, Inc. (NASDAQ:AMGN) have been given an average recommendation of “Buy” by the twenty-five ratings firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $194.92.

Several analysts recently weighed in on the company. TheStreet lowered Amgen from a “b-” rating to a “c+” rating in a report on Wednesday, April 11th. Morgan Stanley lowered their price objective on Amgen from $205.00 to $200.00 and set an “overweight” rating for the company in a report on Wednesday, April 25th. Cowen reissued a “buy” rating and issued a $204.00 price objective on shares of Amgen in a report on Tuesday, April 24th. Zacks Investment Research lowered Amgen from a “buy” rating to a “hold” rating in a report on Tuesday, April 17th. Finally, BidaskClub raised Amgen from a “buy” rating to a “strong-buy” rating in a report on Wednesday.

Shares of Amgen traded up $0.93, reaching $194.08, during midday trading on Friday, according to Marketbeat. 2,251,900 shares of the company’s stock were exchanged, compared to its average volume of 4,090,982. Amgen has a 52-week low of $163.31 and a 52-week high of $201.23. The firm has a market cap of $129.49 billion, a price-to-earnings ratio of 15.43, a PEG ratio of 2.43 and a beta of 1.38. The company has a debt-to-equity ratio of 2.14, a quick ratio of 3.60 and a current ratio of 3.88.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, April 24th. The medical research company reported $3.47 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.24 by $0.23. Amgen had a return on equity of 35.80% and a net margin of 9.67%. The business had revenue of $5.55 billion for the quarter, compared to analyst estimates of $5.44 billion. During the same period in the previous year, the company earned $3.15 earnings per share. The company’s revenue for the quarter was up 1.6% compared to the same quarter last year. research analysts predict that Amgen will post 13.67 EPS for the current year.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction that occurred on Monday, May 14th. The stock was sold at an average price of $174.10, for a total value of $265,502.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.19% of the company’s stock.

Hedge funds have recently modified their holdings of the business. Timber Creek Capital Management LLC lifted its position in Amgen by 1.6% in the fourth quarter. Timber Creek Capital Management LLC now owns 18,672 shares of the medical research company’s stock worth $3,247,000 after purchasing an additional 285 shares during the period. Lee Danner & Bass Inc. lifted its position in Amgen by 0.9% in the fourth quarter. Lee Danner & Bass Inc. now owns 33,524 shares of the medical research company’s stock worth $5,830,000 after purchasing an additional 290 shares during the period. Stanley Laman Group Ltd. lifted its position in Amgen by 8.3% in the first quarter. Stanley Laman Group Ltd. now owns 3,985 shares of the medical research company’s stock worth $679,000 after purchasing an additional 306 shares during the period. Wayne Hummer Investments L.L.C. lifted its position in Amgen by 13.3% in the fourth quarter. Wayne Hummer Investments L.L.C. now owns 2,614 shares of the medical research company’s stock worth $455,000 after purchasing an additional 307 shares during the period. Finally, Bristlecone Advisors LLC lifted its position in Amgen by 1.8% in the fourth quarter. Bristlecone Advisors LLC now owns 17,147 shares of the medical research company’s stock worth $2,982,000 after purchasing an additional 310 shares during the period. Institutional investors own 78.34% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply